Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Authors' reply: Whole-brain radiation therapy—concerns about neurotoxicity

Nature Reviews Clinical Oncology volume 8, page 506 (2011)Cite this article

We thank Padovani and colleagues for their comments and interest in our article: Whole-brain radiation therapy in breast cancer patients with brain metastases. Nat. Rev. Clin. Oncol. 7, 632–6401 (Breast cancer—what about radiosurgery for brain metastasis? Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2010.119-c1).2 As we previously described,3 multidisciplinary discussion is mandatory before the choice of whole-brain radiation therapy (WBRT) and/or radiosurgery, especially in breast cancer patients. The neurotoxicity associated with WBRT is an important concern, in particular for patients whose survival will be long enough to experience delayed neurocognitive dysfunction; however, it has been insufficiently documented in the literature. Most studies used tests lacking both sensitivity and specificity; in addition, chemotherapeutic agents also carry a risk of neurological toxicity, making it difficult to distinguish WBRT-induced neurotoxicity from neurocognitive impairments caused by intracranial progression or decrease in general health status.4 Despite these confounding issues, it was prospectively demonstrated that patients receiving radiosurgery plus WBRT exhibited a greater risk for learning and memory dysfunctions compared with those receiving radiosurgery alone as first-line treatment of their brain metastases.5 We agree with Padovani et al.2 that treatment with radiosurgery alone in conjunction with an accurate MRI-based surveillance is a good strategy for postponing WBRT, but a considerable number of patients cannot be offered radiosurgery because of progressive systemic disease, and/or the number or size of metastases. It is also difficult to draw definitive conclusions from trials that included patients with diverse primary tumors and various associated comorbidities that contribute to neurological toxicity.1

Breast cancer patients are a unique population with specific molecular subtypes that should be taken into account when deciding the optimal primary care of brain metastases. For example, HER2-positive breast cancers have a propensity to metastasize to the brain.6 Intracranial progression outside the tumor bed is an important factor related to death and loss of autonomy in this population, encouraging new strategies for improving intracranial control.7 Moreover, the neurocognitive effects of intracranial progression are not negligible. While the combination of WBRT and radiosurgery decreases brain relapse compared with radiosurgery alone,8 new irradiation modalities combining WBRT, boosts to the tumor beds, and sparing of critical structures could ensure both good intracranial control and low neurotoxicity.9 This should be prospectively confirmed. The place for targeted systemic therapies should also be further considered for improving patients' outcome.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chargari, C. et al. Whole-brain radiation therapy in breast cancer patients with brain metastases. Nat. Rev. Clin. Oncol. 7, 632–640 (2010).

    Article  Google Scholar 

  2. Padovani, L. et al. Breast cancer—what about radiosurgery for brain metastasis? Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2010.119-c1.

    Article  Google Scholar 

  3. Kirova, Y., Chargari, C. & Mazeron, J. J. Multiple brain metastases after breast cancer and their radiotherapy management: what is the optimal treatment? Bull. Cancer 98, 409–415 (2011).

    PubMed  Google Scholar 

  4. Ricard, D. et al. Brain damage from anticancer treatments in adults. Curr. Opin. Oncol. 21, 559–565 (2009).

    Article  CAS  Google Scholar 

  5. Chang, E. L. et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10, 1037–1044 (2009).

    Article  Google Scholar 

  6. Wolstenholme, V., Hawkins, M., Ashley, S., Tait, D. & Ross, G. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast 17, 661–665 (2008).

    Article  Google Scholar 

  7. Chargari, C. et al. Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. doi:10.1016/j.ijrobp.2010.06.057.

    Article  Google Scholar 

  8. Patchell, R. A. et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485–1489 (1998).

    Article  CAS  Google Scholar 

  9. Hsu, F. et al. Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1–3 brain metastases: a feasibility study using volumetric modulated arc therapy. Int. J. Radiat. Oncol. Biol. Phys. 76, 1480–1485 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical and Radiation Oncology Unit Hôpital d'Instruction des Armées du Val-de-Grâce, 74 Boulevard de Port Royal, 75230 Paris Cedex 5, France

    Cyrus Chargari

  2. Department of Radiation Oncology, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 5, France

    Youlia M. Kirova

Authors
  1. Cyrus Chargari
    View author publications

    Search author on:PubMed Google Scholar

  2. Youlia M. Kirova
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Cyrus Chargari.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chargari, C., Kirova, Y. Authors' reply: Whole-brain radiation therapy—concerns about neurotoxicity. Nat Rev Clin Oncol 8, 506 (2011). https://doi.org/10.1038/nrclinonc.2010.119-c2

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.119-c2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing